Lamotrigine
Product manufactured by Zydus Pharmaceuticals (usa) Inc.
Indications and Purposes
| 1 Indications And Usage Lamotrigine Extended-Release Tablets Are Indicated For: Adjunctive Therapy For Primary Generalized Tonic-Clonic Seizures And Partial-Onset Seizures With Or Without Secondary Generalization In Patients Aged 13 Years And Older. (1.1) Conversion To Monotherapy In Patients Aged 13 Years And Older With Partial-Onset Seizures Who Are Receiving Treatment With A Single Antiepileptic Drug. (1.2) Limitation Of Use: Safety And Effectiveness In Patients Younger Than 13 Years Have Not Been Established. (1.3) 1.1 Adjunctive Therapy Lamotrigine Extended-Release Tablets Are Indicated As Adjunctive Therapy For Primary Generalized Tonic-Clonic (pgtc) Seizures And Partial-Onset Seizures With Or Without Secondary Generalization In Patients Aged 13 Years And Older. 1.2 Monotherapy Lamotrigine Extended-Release Tablets Are Indicated For Conversion To Monotherapy In Patients Aged 13 Years And Older With Partial-Onset Seizures Who Are Receiving Treatment With A Single Antiepileptic Drug (aed). Safety And Effectiveness Of Lamotrigine Extended-Release Have Not Been Established (1) As Initial Monotherapy Or (2) For Simultaneous Conversion To Monotherapy From 2 Or More Concomitant Aeds. 1.3 Limitation Of Use Safety And Effectiveness Of Lamotrigine Extended-Release For Use In Patients Younger Than 13 Years Have Not Been Established. |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Lamotrigine |
|
ZINC13156 |